|
HYPERPRORENINEMIA, FAMILIAL
|
0.100 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Abnormality of the urinary system
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Tubular Atrophy Assessment
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
RGD |
"Inhibition of diabetic nephropathy by a decoy peptide corresponding to the ""handle"" region for nonproteolytic activation of prorenin."
|
15489960 |
2004 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
<b>:</b> The renin-angiotensin receptor AT2R controls systemic blood pressure and is also suggested to modulate metastasis of cancer cells.
|
31484460 |
2019 |
|
Chronic Kidney Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
<b>Abbreviations</b>: Angiotensin-converting enzyme (ACE); Angiotensin converting enzyme inhibitors (ACEIs); Angiotensin II (ANG II); Analysis of variance (ANOVA); Angiotensin receptor blockers (ARBs); Blood Pressure (BP); Calcium Antagonists Calcium Channel Blockers (CCB); Chronic kidney diseases (CKD); Sodium carboxyl methyl cellulose (CMC-Na); Cardiac mass index (CMI); Cardiovascular diseases (CVD); Diastolic blood pressure (DBP); Enzyme-linked immunosorbent assay (ELISA); Hematoxylin-eosin (H&E); Kidney mass index (KMI); Liver mass index (LMI); Mean arterial blood pressure (MAP); Plasma renin concentration (PRC); Renin-angiotensin system (RAS); Rennin (REN); Systolic blood pressure (SBP); Student-Newman-Keuls q test (SNK-q test); Spontaneous hypertension rats (SHR); Valsartan asleep Administration (VSA); Valsartan awake Administration (VWA); Wistar-Kyoto (WKY); Mesor (M); Amplitude (A); Phase (φ).
|
31096810 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
<b>Abbreviations</b>: Angiotensin-converting enzyme (ACE); Angiotensin converting enzyme inhibitors (ACEIs); Angiotensin II (ANG II); Analysis of variance (ANOVA); Angiotensin receptor blockers (ARBs); Blood Pressure (BP); Calcium Antagonists Calcium Channel Blockers (CCB); Chronic kidney diseases (CKD); Sodium carboxyl methyl cellulose (CMC-Na); Cardiac mass index (CMI); Cardiovascular diseases (CVD); Diastolic blood pressure (DBP); Enzyme-linked immunosorbent assay (ELISA); Hematoxylin-eosin (H&E); Kidney mass index (KMI); Liver mass index (LMI); Mean arterial blood pressure (MAP); Plasma renin concentration (PRC); Renin-angiotensin system (RAS); Rennin (REN); Systolic blood pressure (SBP); Student-Newman-Keuls q test (SNK-q test); Spontaneous hypertension rats (SHR); Valsartan asleep Administration (VSA); Valsartan awake Administration (VWA); Wistar-Kyoto (WKY); Mesor (M); Amplitude (A); Phase (φ).
|
31096810 |
2019 |
|
Liver mass
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
<b>Abbreviations</b>: Angiotensin-converting enzyme (ACE); Angiotensin converting enzyme inhibitors (ACEIs); Angiotensin II (ANG II); Analysis of variance (ANOVA); Angiotensin receptor blockers (ARBs); Blood Pressure (BP); Calcium Antagonists Calcium Channel Blockers (CCB); Chronic kidney diseases (CKD); Sodium carboxyl methyl cellulose (CMC-Na); Cardiac mass index (CMI); Cardiovascular diseases (CVD); Diastolic blood pressure (DBP); Enzyme-linked immunosorbent assay (ELISA); Hematoxylin-eosin (H&E); Kidney mass index (KMI); Liver mass index (LMI); Mean arterial blood pressure (MAP); Plasma renin concentration (PRC); Renin-angiotensin system (RAS); Rennin (REN); Systolic blood pressure (SBP); Student-Newman-Keuls q test (SNK-q test); Spontaneous hypertension rats (SHR); Valsartan asleep Administration (VSA); Valsartan awake Administration (VWA); Wistar-Kyoto (WKY); Mesor (M); Amplitude (A); Phase (φ).
|
31096810 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations: BP</b> = blood pressure; <b>CKD</b> = chronic kidney disease; <b>CT</b> = computed tomography; <b>ESRD</b> = end-stage renal disease; <b>FFA</b> = free fatty acid; <b>FKD</b> = fatty kidney disease; <b>GFR</b> = glomerular filtration rate; <b>MetS</b> = metabolic syndrome; <b>MRI</b> = magnetic resonance imaging; <b>NAFLD</b> = nonalcoholic fatty liver disease; <b>RAAS</b> = renin-angiotensin system; <b>SGLT2</b> = sodium-glucose cotransporter 2; <b>SNS</b> = sympathetic nervous system; <b>T2D</b> = type 2 diabetes; <b>TG</b> = triglyceride.
|
31013163 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations: BP</b> = blood pressure; <b>CKD</b> = chronic kidney disease; <b>CT</b> = computed tomography; <b>ESRD</b> = end-stage renal disease; <b>FFA</b> = free fatty acid; <b>FKD</b> = fatty kidney disease; <b>GFR</b> = glomerular filtration rate; <b>MetS</b> = metabolic syndrome; <b>MRI</b> = magnetic resonance imaging; <b>NAFLD</b> = nonalcoholic fatty liver disease; <b>RAAS</b> = renin-angiotensin system; <b>SGLT2</b> = sodium-glucose cotransporter 2; <b>SNS</b> = sympathetic nervous system; <b>T2D</b> = type 2 diabetes; <b>TG</b> = triglyceride.
|
31013163 |
2019 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
<b>Aims:</b> Renal renin-angiotensin system (RAS) plays a pivotal role in the development of diabetic nephropathy (DN).
|
29056916 |
2017 |
|
Vascular Diseases
|
0.080 |
Biomarker
|
group |
BEFREE |
<b>Aims:</b> The renin-angiotensin system (RAS) plays an important role in the pathophysiology of vascular diseases, especially as a mediator of inflammation and tissue remodelling.
|
30737255 |
2019 |
|
Chronic Kidney Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
<b>Areas covered</b>: This review focuses on those tested in phase III clinical trials for the treatment of CKD in diabetic patients, including renin-angiotensin system blockers, aldosterone antagonists, calcium channel blockers, TGF-β inhibitors, protein kinase C inhibitors, advanced glycation end products inhibitors, GLP-1 analogues, DPP-4 inhibitors, SGLT2 inhibitors, endothelin receptor antagonists, and so on.
|
30509118 |
2019 |
|
Hypertension, Renovascular
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> Naringenin attenuated renal damage in a rat model of renovascular hypertension by normalizing the imbalance of renin-angiotensin system activation.
|
31217731 |
2019 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
<b>Introduction</b>: Renin-angiotensin system (RAS) blockers are in clinical use to treat high blood pressure and proteinuric chronic kidney disease.
|
30412432 |
2019 |
|
Chronic Kidney Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
<b>Introduction</b>: Renin-angiotensin system (RAS) blockers are in clinical use to treat high blood pressure and proteinuric chronic kidney disease.
|
30412432 |
2019 |
|
Nephrotic Syndrome, Minimal Change
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Introduction:</b> Renin angiotensin system (RAS) plays a role in idiopathic nephrotic syndrome (INS).
|
30514826 |
2019 |
|
Idiopathic Nephrotic Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Introduction:</b> Renin angiotensin system (RAS) plays a role in idiopathic nephrotic syndrome (INS).
|
30514826 |
2019 |
|
Infantile nystagmus syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Introduction:</b> Renin angiotensin system (RAS) plays a role in idiopathic nephrotic syndrome (INS).
|
30514826 |
2019 |
|
Chronic Kidney Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
(1) The incidence of CKD using Cox regression and (2) the course of kidney function (estimated glomerular filtration rate [eGFR] and 24-hour albuminuria) over 5 visits using generalized estimating equation analysis adjusted for age, mean arterial pressure, and renin-angiotensin system (RAS) blockade.
|
29289477 |
2018 |
|
Invasive Carcinoma
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
(2) (pro)renin was identified in epithelial cells in both normal and diseased tissue, but in invasive carcinoma, its distribution was mostly confined to fibroblasts or could not be detected at all.
|
16755291 |
2006 |
|
Conn Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
(ii) Plasma aldosterone levels after a saline infusion test, plasma renin, and 24-hour urine steroid hormone metabolome and hemodynamic parameters were measured during an open-label study in 12 patients with PA, before and after 2 weeks of treatment with everolimus and after a 2-week washout.
|
31087053 |
2019 |
|
Diabetic Nephropathy
|
0.300 |
Biomarker
|
disease |
BEFREE |
(Pro)renin receptor ((P)RR), a specific receptor for renin and prorenin, is a 350 amino-acid protein with a single transmembrane domain and may play important pathophysiological roles in diabetic nephropathy.
|
20385187 |
2010 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
(Pro)renin receptor (PRR), a novel member of the renin-angiotensin system, participates in various cardiovascular diseases.
|
31498445 |
2019 |
|
Proliferative diabetic retinopathy
|
0.020 |
Biomarker
|
disease |
BEFREE |
(Pro)renin receptor [(P)RR], a new component of the tissue renin-angiotensin system (RAS), plays a crucial role in inflammation and angiogenesis in the eye, thus contributing to the development of proliferative diabetic retinopathy (PDR).
|
29240802 |
2017 |